AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9139277 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant patients (on three or more drugs)
Number of subjects: 299
Study 9139277 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with essential hypertension resistant to treatment
Number of subjects: 299
Study 9139277 — intervention group
Group type: COMPARATOR
Intervention: Patients with essential hypertension responsive to antihypertensive treatment
Number of subjects: 299
Study 9139277 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with essential hypertension
Number of subjects: 299
Study 1897471 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 129
Study 1897471 — intervention group
Group type: COMPARATOR
Intervention: Stimulation
Number of subjects: 129
Study 1897471 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 129
Study 1897471 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study 6315911 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana (20 mg doses of delta‐9 tetrahydrocannabinol)
Number of subjects: 72
Study 6315911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 31542292 — intervention group
Group type: EXPERIMENTAL
Intervention: Early combination therapy with vildagliptin (50 mg twice daily) and metformin (stable daily dose of 1000 mg, 1500 mg, or 2000 mg)
Number of subjects: 2001
Study 31542292 — intervention group
Group type: COMPARATOR
Intervention: Initial metformin monotherapy (stable daily dose of 1000 mg, 1500 mg, or 2000 mg) and placebo twice daily
Number of subjects: 2001
Study 31542292 — intervention group
Group type: EXPERIMENTAL
Intervention: Early combination therapy with vildagliptin and metformin
Number of subjects: 2001
Study 31542292 — intervention group
Group type: COMPARATOR
Intervention: Initial metformin monotherapy
Number of subjects: 2001
Study 30168131 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 30168131 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0
Study 30168131 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study 30168131 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 0
Study 26634774 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-literacy action plan
Number of subjects: 119
Study 26634774 — intervention group
Group type: COMPARATOR
Intervention: Standard action plan
Number of subjects: 119
Study 24564723 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular training (average of 14.5 sessions over 4 to 6 weeks)
Number of subjects: 22
Study 21827371 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention training condition
Number of subjects: 0
Study 21827371 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 20339846 — intervention group
Group type: EXPERIMENTAL
Intervention: TPO mimetics (romiplostim and eltrombopag)
Number of subjects: 0
Study 20339846 — intervention group
Group type: COMPARATOR
Intervention: Standard treatments
Number of subjects: 0
Study 16522696 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conivaptan 40 mg/d
Number of subjects: 74
Study 16522696 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conivaptan 80 mg/d
Number of subjects: 74
Study 16522696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 12709315 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine + Rifampin
Number of subjects: 59
Study 12709315 — intervention group
Group type: COMPARATOR
Intervention: Quinine alone
Number of subjects: 59
Study 10922169 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitek VK II system
Number of subjects: 62
Study 10922169 — intervention group
Group type: EXPERIMENTAL
Intervention: Christensen system
Number of subjects: 62
Study 10922169 — intervention group
Group type: COMPARATOR
Intervention: Preoperative condition
Number of subjects: 62
Study 10922169 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative condition
Number of subjects: 62
Study 10922169 — intervention group
Group type: COMPARATOR
Intervention: Preoperative pain
Number of subjects: 62
Study 10922169 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain
Number of subjects: 62
Study 10922169 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success rate
Number of subjects: 62
Study 8928604 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane with 50% nitrous oxide
Number of subjects: 53
Study 8928604 — intervention group
Group type: COMPARATOR
Intervention: Propofol with 50% nitrous oxide
Number of subjects: 53
Study 8928604 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study 1570949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed protein formula
Number of subjects: 60
Study 1570949 — intervention group
Group type: COMPARATOR
Intervention: Conventional modified milk formula
Number of subjects: 60
Study 6242249 — intervention group
Group type: EXPERIMENTAL
Intervention: Total serum hexosaminidase levels in subjects with female genital cancers
Number of subjects: 0
Study 6242249 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐hexosaminidase levels in subjects with genital cancer
Number of subjects: 0
Study 6242249 — intervention group
Group type: COMPARATOR
Intervention: Total and beta‐hexosaminidase levels
Number of subjects: 0
Study 31843375 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMPL‐SYNC refill synchronization (SSRS)
Number of subjects: 190
Study 31843375 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 190
Study 31456010 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mizolastine (10 mg/day), proteoglycan (1.2 g, 3 times/day), calcium gluconate (10 mg/day), vitamin D3 (10 mg/week)
Number of subjects: 100
Study 31456010 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mizolastine and proteoglycan
Number of subjects: 100
Study 28315567 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossing septum guided by track image mapped by Carto3 system (track group)
Number of subjects: 40
Study 28315567 — intervention group
Group type: COMPARATOR
Intervention: Crossing interatrial septum guided by fluoroscopy (trackless group)
Number of subjects: 40
Study 28315567 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (track group and trackless group)
Number of subjects: 40
Study 25497694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 5 years
Number of subjects: 7154
Study 23928867 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin added to intensive insulin therapy
Number of subjects: 33
Study 23928867 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone (control group)
Number of subjects: 33
Study 20708320 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-treated group
Number of subjects: 219
Study 20708320 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 219
Study 19538812 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 g additional fruit and vegetables per day
Number of subjects: 276
Study 19538812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 19538812 — intervention group
Group type: COMPARATOR
Intervention: Potassium citrate
Number of subjects: 276
Study 16488337 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab therapy
Number of subjects: 339
Study 15465402 — intervention group
Group type: EXPERIMENTAL
Intervention: PDQL-EV questionnaire
Number of subjects: 137
Study 11782701 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil
Number of subjects: 40
Study 11782701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9875909 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric feeding
Number of subjects: 20
Study 9875909 — intervention group
Group type: COMPARATOR
Intervention: Postpyloric feeding
Number of subjects: 20
Study 8034151 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group education
Number of subjects: 68
Study 8034151 — intervention group
Group type: COMPARATOR
Intervention: Individual counselling
Number of subjects: 68
Study 2659104 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage hormonal therapy
Number of subjects: 257
Study 2659104 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy
Number of subjects: 257
Study 2659104 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with CFP as salvage chemotherapy
Number of subjects: 257
Study 2659104 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage CFP
Number of subjects: 257
Study 4281729 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study 4281729 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated children)
Number of subjects: 0
Study 31113415 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour intervention revealing safer sex option: dating same-age partners
Number of subjects: 229
Study 28154373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol 2.5/5 or 5/5 μg
Number of subjects: 6783
Study 28154373 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 2.5 or 5 μg
Number of subjects: 6783
Study 28154373 — intervention group
Group type: COMPARATOR
Intervention: Olodaterol 5 μg
Number of subjects: 6783
Study 28154373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6783
Study 28154373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol 5/5 μg
Number of subjects: 6783
Study 25666530 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (7 ± 3% weight loss)
Number of subjects: 161
Study 25666530 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery (33 ± 9% weight loss)
Number of subjects: 161
Study 23385499 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine and 1% thymol varnish (CervitecPlus)
Number of subjects: 60
Study 23385499 — intervention group
Group type: EXPERIMENTAL
Intervention: CervitecPlus + 0.2% chlorhexidine and 0.2% sodium fluoride (CervitecGel)
Number of subjects: 60
Study 23385499 — intervention group
Group type: COMPARATOR
Intervention: 0.1% fluoride varnish (Fluor Protector)
Number of subjects: 60
Study 22018187 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 5 mg/day
Number of subjects: 192
Study 22018187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 20467635 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of implants
Number of subjects: 30
Study 20467635 — intervention group
Group type: COMPARATOR
Intervention: Early loading of implants
Number of subjects: 30
Study 16533077 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct selection
Number of subjects: 120
Study 16533077 — intervention group
Group type: COMPARATOR
Intervention: Visual linear scanning
Number of subjects: 120
Study 16533077 — intervention group
Group type: EXPERIMENTAL
Intervention: 3rd-grade children
Number of subjects: 120
Study 16533077 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval errors
Number of subjects: 120
Study 14652118 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at a subhypnotic dose (1.0 mg/kg/hr)
Number of subjects: 100
Study 14652118 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 100
Study 14652118 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 100
Study 14652118 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study 11742887 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg) plus pyridoxine (250 mg)
Number of subjects: 158
Study 11742887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 9420110 — intervention group
Group type: EXPERIMENTAL
Intervention: DCP without BG
Number of subjects: 91
Study 9420110 — intervention group
Group type: EXPERIMENTAL
Intervention: DCP with BG
Number of subjects: 91
Study 9420110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ender nails (EN)
Number of subjects: 91
Study 8498758 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline, 100 mg nightly for 7 days
Number of subjects: 253
Study 8498758 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline, 100 mg twice daily for 7 days
Number of subjects: 253
Study 3281765 — intervention group
Group type: COMPARATOR
Intervention: Saline bolus followed by saline infusion
Number of subjects: 29
Study 3281765 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 microgram.kg‐1 naloxone bolus followed by 0.4 microgram.kg‐1.hr‐1 naloxone infusion
Number of subjects: 29
Study 3281765 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 micrograms.kg‐1 naloxone bolus followed by 2.0 micrograms.kg‐1.hr‐1 naloxone infusion
Number of subjects: 29
Study 3281765 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 micrograms.kg‐1 naloxone bolus followed by 4.0 micrograms.kg‐1.hr‐1 naloxone infusion
Number of subjects: 29
Study 30271119 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular targeted agents (MTAs)
Number of subjects: 4716
Study 30271119 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib
Number of subjects: 4716
Study 30271119 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 4716
Study 30271119 — intervention group
Group type: EXPERIMENTAL
Intervention: Other molecular targeted agents (MTAs)
Number of subjects: 4716
Study 29132441 — intervention group
Group type: EXPERIMENTAL
Intervention: Early screening and treatment for genital Chlamydia trachomatis infection over 24 months.
Number of subjects: 4000
Study 29132441 — intervention group
Group type: COMPARATOR
Intervention: Control group with vaginal swabs analyzed at the end of the study following current recommendations.
Number of subjects: 4000
Study 25160589 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐3577 (0‐900 mg)
Number of subjects: 36
Study 25160589 — intervention group
Group type: COMPARATOR
Intervention: Glucagon, octreotide (Sandostatin), and basal insulin infusion
Number of subjects: 36
Study 25160589 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear model for fasting plasma glucose (FPG)
Number of subjects: 36
Study 22751354 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal Fast ForWord training (Group A)
Number of subjects: 30
Study 22751354 — intervention group
Group type: COMPARATOR
Intervention: Non-temporal control training (Group B)
Number of subjects: 30
Study 22751354 — intervention group
Group type: COMPARATOR
Intervention: Non-active controls (Group C)
Number of subjects: 30
Study 20017187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (4-month prospective study)
Number of subjects: 247
Study 20017187 — intervention group
Group type: COMPARATOR
Intervention: High perceived physical workload or overtime work
Number of subjects: 247
Study 20017187 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline pain intensity, Hispanic ethnicity, and taking cumulative daily rest time of 35 min or more
Number of subjects: 247
Study 17351226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 100
Study 17351226 — intervention group
Group type: COMPARATOR
Intervention: Mackintosh laryngoscope
Number of subjects: 100
Study 16244851 — intervention group
Group type: EXPERIMENTAL
Intervention: Health telephone surveys
Number of subjects: 8313
Study 11889385 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastoid pneumatization measurement (size measured by simplified rectangular dimension method on a mastoid x-ray)
Number of subjects: 24
Study 11889385 — intervention group
Group type: COMPARATOR
Intervention: Ears with barotrauma
Number of subjects: 24
Study 9459076 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative search condition
Number of subjects: 30
Study 9459076 — intervention group
Group type: COMPARATOR
Intervention: Positive search condition
Number of subjects: 30
Study 9459076 — intervention group
Group type: COMPARATOR
Intervention: Known intervals search condition
Number of subjects: 30
Study 9497653 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline‐Hcl solution 100 mg/ml for 5 minutes
Number of subjects: 7
Study 9497653 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tetracycline irrigation)
Number of subjects: 7
Study 2559794 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus extract, administered orally for 1 month
Number of subjects: 0
Study 2559794 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus extract, administered intraperitoneally
Number of subjects: 0
Study 370685 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified neurotoxin
Number of subjects: 48
Study 370685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30824257 — intervention group
Group type: EXPERIMENTAL
Intervention: CAU + online intervention (mindfulness-based compassionate living, MBCL)
Number of subjects: 122
Study 30824257 — intervention group
Group type: COMPARATOR
Intervention: CAU (care as usual)
Number of subjects: 122
Study 27219124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C (3 g in 500 mL of Ringer)
Number of subjects: 40
Study 27219124 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (6 mL in 500 mL of Ringer)
Number of subjects: 40
Study 27219124 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Vitamin C and Normal Saline)
Number of subjects: 40
Study 24820007 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine pericardium mesh
Number of subjects: 40
Study 24820007 — intervention group
Group type: COMPARATOR
Intervention: Routine abdominal suture closure (Control)
Number of subjects: 40
Study 23643338 — intervention group
Group type: EXPERIMENTAL
Intervention: SS‐SSTP (Second Step: Student Success Through Prevention)
Number of subjects: 3616
Study 23643338 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 3616
Study 20350769 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment (LLT) group, including statin and/or fibrate
Number of subjects: 510
Study 20350769 — intervention group
Group type: COMPARATOR
Intervention: No-Lipid-lowering treatment (No-LLT) group
Number of subjects: 510
Study 19269925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation + vocational rehabilitation
Number of subjects: 34
Study 19269925 — intervention group
Group type: COMPARATOR
Intervention: Vocational rehabilitation alone
Number of subjects: 34
Study 16643536 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 40
Study 16643536 — intervention group
Group type: COMPARATOR
Intervention: High-speed excavation
Number of subjects: 40
Study 12671333 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous treatment of hypertension and use of converting‐enzyme inhibitors
Number of subjects: 0
Study 12671333 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers
Number of subjects: 0
Study 12671333 — intervention group
Group type: EXPERIMENTAL
Intervention: Various drugs
Number of subjects: 0
Study 12497780 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 1.5 mg daily
Number of subjects: 0
Study 12497780 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg daily
Number of subjects: 0
Study 7549804 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid diet (carrots and spinach)
Number of subjects: 19
Study 7549804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciferous diet (broccoli and cauliflower)
Number of subjects: 19
Study 7549804 — intervention group
Group type: COMPARATOR
Intervention: Control diet (essentially carotenoid free)
Number of subjects: 19
Study 1718694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarenal gallopamil plus intravenous furosemide (0.5 mg/kg/h for 24 hours)
Number of subjects: 10
Study 1718694 — intervention group
Group type: COMPARATOR
Intervention: Furosemide alone
Number of subjects: 10
Study 6958406 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of preventive regimens including fluoridated water ingestion, oral hygiene education, dental examinations, prophylaxis, acidulated phosphate fluoride gel (1.23%), pit and fissure sealants, and restorative care
Number of subjects: 1286
Study 6958406 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group that continued with preventive regimens
Number of subjects: 1286
Study 6958406 — intervention group
Group type: COMPARATOR
Intervention: Treatment group that did not continue with treatment after 3 years
Number of subjects: 1286
Study 31297906 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 68
Study 31294447 — intervention group
Group type: EXPERIMENTAL
Intervention: Homologous recombination (HR) pathway
Number of subjects: 0
Study 31294447 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Holliday junction (dHJ) pathway
Number of subjects: 0
Study 31294447 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthesis-dependent strand annealing (SDSA)
Number of subjects: 0
Study 31294447 — intervention group
Group type: EXPERIMENTAL
Intervention: Break-induced replication (BIR)
Number of subjects: 0
Study 31294447 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-strand annealing (SSA)
Number of subjects: 0
Study 28610582 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training for 5 weeks
Number of subjects: 28
Study 28610582 — intervention group
Group type: COMPARATOR
Intervention: Habitual activity (control group)
Number of subjects: 28
Study 26238090 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 23359237 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% fraction of inspired oxygen (FIO2)
Number of subjects: 160
Study 23359237 — intervention group
Group type: COMPARATOR
Intervention: 30% fraction of inspired oxygen (FIO2)
Number of subjects: 160
Study 22080021 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% millet inclusion
Number of subjects: 432
Study 22080021 — intervention group
Group type: COMPARATOR
Intervention: Millet growth condition
Number of subjects: 432
Study 22080021 — intervention group
Group type: COMPARATOR
Intervention: Millet inclusion level
Number of subjects: 432
Study 18359416 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida colonization
Number of subjects: 639
Study 16484309 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1200 mg daily during menses for up to 5 days each cycle for the first 6 months)
Number of subjects: 2019